secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000950170-22-023224
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio Q3 net loss $22M; ADI-001 shows 78% ORR/CR, pivotal program planned H1 2023
--------------------------------------------------------------------------------

- Net loss of $22.0M ($0.53 per share) vs $14.0M in Q3 2021; R&D expenses rose to $16.6M.
- Cash and cash equivalents $282.7M as of Sep 30, 2022; runway into first half of 2025.
- ADI-001 Phase 1 data: 78% ORR and CR (7/9) in relapsed/refractory B-cell NHL; 100% in prior CAR-T patients.
- Expects to initiate a potentially pivotal program for ADI-001 in the first half of 2023.
- In-house manufacturing in Redwood City expected operational in Q4 2022; R&D webcast Nov 10, ASH update Dec 11.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017022023224/0000950170-22-023224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017022023224/acet-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer